Ibd Research
Ibd Research - Related Videos
01:29
Drugs for Treatment of Ulcerative Colitis in IBD
0 Views •
2024
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
0 Views •
Cited by 607 •
2012
Experimental models of inflammatory bowel disease have allowed us to examine the complex innate and adaptive immune responses associated with pathogenesis. Using histological scoring, quantification of pro-inflammatory cytokines and myeloperoxidase activity, one can begin to assess these responses seen in inflammatory bowel disease.
01:21
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
0 Views •
2024
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
0 Views •
2024
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
0 Views •
2024
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
FAQs
IBD research examines these factors as an interconnected system rather than as isolated causes. Genetic susceptibility may shape how the intestine responds, while barrier dysfunction can alter contact between intestinal contents and immune defenses. Changes involving gut microbiota and dysregulated immune responses may then help initiate or sustain inflammation, giving researchers several linked processes to investigate.
Host-microbe interactions help researchers examine how intestinal biology and gut microbiota influence one another during disease. This perspective connects microbial changes with barrier dysfunction and immune dysregulation, potentially clarifying why inflammation persists. It also supports research aimed at identifying disease mechanisms, improving monitoring, and developing approaches that account for differences between patients.
Studies focus on the transition from susceptibility to ongoing gastrointestinal inflammation and injury. Researchers examine genetic factors, the integrity of the intestinal barrier, gut microbiota, and immune responses to determine how these elements interact over time. Understanding their combined contribution may reveal mechanisms that support earlier diagnosis, more precise disease monitoring, and targeted treatment development.
Investigators commonly combine patient samples, animal models, organoids, and molecular analyses. Patient samples provide material connected to human disease, while animal models and organoids offer experimental systems for examining intestinal and inflammatory processes. Molecular analyses help characterize the factors involved. Using these complementary approaches can connect biological mechanisms with clinically relevant observations.
Research seeks biological information that can support earlier diagnosis and more informative assessment of disease activity. By analyzing patient samples and molecular features alongside studies of barrier, microbial, and immune processes, investigators can examine indicators associated with inflammation and injury. These efforts may improve the ability to track disease status and evaluate whether inflammation remains controlled.
Findings from IBD research support development of targeted therapies intended to reduce inflammation and maintain remission. Research also examines how genetic susceptibility, microbiota, barrier function, and immune responses vary or interact, creating a foundation for more personalized approaches to treatment and prevention. In biology, this work also advances understanding of host-microbe relationships in chronic disease.